Nanomedicine, Volume IIA: Biocompatibility

© 2003 Robert A. Freitas Jr. All Rights Reserved.

Robert A. Freitas Jr., Nanomedicine, Volume IIA: Biocompatibility, Landes Bioscience, Georgetown, TX, 2003


References 1600-1699

1600. C.J. Allender, C. Richardson, B. Woodhouse, C.M. Heard, K.R. Brain, “Pharmaceutical applications for molecularly imprinted polymers,” Int. J. Pharm. 195(15 February 2000):39-43; C.J. Allender, K.R. Brain, C.M. Heard, “Molecularly imprinted polymers--preparation, biomedical applications and technical challenges,” Prog. Med. Chem. 36(1999):235-291.

1601. O. Ramstrom, L. Ye, K. Mosbach, “Artificial antibodies to corticosteroids prepared by molecular imprinting,” Chem. Biol. 3(June 1996):471-477.

1602. G. Wulff, “Imprinting techniques in synthetic polymers – new options for chemosensors,” EXS 80(1997):13-26.

1603. B.D. Ratner, “The engineering of biomaterials exhibiting recognition and specificity,” J. Mol. Recognit. 9(September-December 1996):617-625.

1604. Philip G. Collins, Keith Bradley, Masa Ishigami, A. Zettl, “Extreme Oxygen Sensitivity of Electronic Properties of Carbon Nanotubes,” Science 287(10 March 2000):1801-1804.

1605. L.J. Paradise, H. Friedman, M. Bendinelli, eds., Opportunistic Intracellular Pathogens and Immunity, Plenum Press, New York, 1999.

1606. M. Matsushita, “Activation mechanism of the complement system,” Nippon Rinsho 57(February 1999):291-297. In Japanese.

1607. T. Fujita, “Evolution of the lectin-complement pathway and its role in innate immunity,” Nature Rev. Immunol. 2(May 2002):346-353; G.R. Vasta, M. Quesenberry, H. Ahmed, N. O’Leary, “C-type tectins and galectins mediate innate and adaptive immune functions: their roles in the complement activation pathway,” Dev. Comp. Immunol. 23(June-July 1999):401-420.

1608. R. Malhotra, J. Lu, U. Holmskov, R.B. Sim, “Collectins, collectin receptors and the lectin pathway of complement activation,” Clin. Exp. Immunol. 97(August 1994):4-9 (Suppl 2).

1609. M.W. Turner, “The lectin pathway of complement activation,” Res. Immunol. 147(February 1996):110-115.

1610. M. Matsushita, “The lectin pathway of the complement system,” Microbiol. Immunol. 40(1996):887-893.

1611. T. Vorup-Jensen, J.C. Jensenius, S. Thiel, “MASP-2, the C3 convertase generating protease of the MBLectin complement activating pathway,” Immunobiology 1999(August 1998):348-357.

1612. Y. Zhang, C. Suankratay, X.H. Zhang, T.F. Lint, H. Gewurz, “Lysis via the lectin pathway of complement activation: minireview and lectin pathway enhancement of endotoxin-initiated hemolysis,” Immunopharmacology 42(May 1999):81-90.

1613. B.P. Morgan, “Regulation of the complement membrane attack pathway,” Crit. Rev. Immunol. 19(1999):173-198.

1614. J. Tschopp, “Ultrastructure of the membrane attack complex of complement. Heterogeneity of the complex caused by different degree of C9 polymerization,” J. Biol. Chem. 259(25 June 1984):7857-7863.

1615. A.F. Esser, “The membrane attack complex of complement. Assembly, structure and cytotoxic activity,” Toxicology 87(28 February 1994):229-247.

1616. H.J. Muller-Eberhard, “The membrane attack complex of complement,” Annu. Rev. Immunol. 4(1986):503-528; “The membrane attack complex,” Springer Semin. Immunopathol. 7(1984):93-141; “Complement,” Annu. Rev. Biochem. 44(1975):697-724.

1617. M. Loos, “The Complement System: Actvation and Control,” in Michael Loos, ed., Bacteria and Complement, Springer-Verlag, New York, 1985, pp. 7-18.

1618. Ivan M. Roitt, Jonathan Brostoff, David K. Male, Immunology, Gower Medical Publishing, New York, 1989.

1619. K.A. Davies, “Complement,” Baillieres Clin. Haematol. 4(December 1991):927-955.

1620. Thomas J. Spira, “Terminal complement component deficiencies (C5, C6, C7, C8, C9),” in J. Willis Hurst, ed., Medicine for the Practicing Physician, Third Edition, Butterworth-Heinemann, Boston MA, 1992, pp. 159-161.

1621. B.P. Morgan, “Physiology and pathphysiology of complement: progress and trends,” Crit. Rev. Clin. Lab. Sci. 32(1995):265-298.

1622. M.K. Liszewski, T.C. Farries, D.M. Lublin, I.A. Rooney, J.P. Atkinson, “Control of the complement system,” Adv. Immunol. 61(1996):201-283.

1623. K. Rother, G.O. Till, G.M. Hansch, eds., The Complement System, Second Revised Edition, Springer-verlag, New York, 1998.

1624. Bernard J. Morley, Mark J. Walport, The Complement Factsbook, Academic Press, New York, 1999.

1625. P.J. Lachmann, “The control of homologous lysis,” Immunol. Today 12(September 1991):312-315; “Protection against complement lysis,” Biochem. Soc. Trans. 18(December 1990):1159-1160.

1626. M. Loos, “Antibody-independent activation of C1, the first component of complement,” Ann. Immunol. (Paris) 133C(1982):165-179.

1627. R.G. DiScipio, C. Berlin, “The architectural transition of human complement component C9 to poly(C9),” Mol. Immunol. 36(June 1999):575-585.

1628. E.R. Podack, J. Tschopp, “Polymerization of the ninth component of complement (C9): formation of poly(C9) with a tubular ultrastructure resembling the membrane attack complex of complement,” Proc. Natl. Acad. Sci. (USA) 79(January 1982):574-578.

1629. R.G. DiScipio, T.E. Hugli, “The architecture of complement component C9 and poly(C9),” J. Biol. Chem. 260(25 November 1985):14802-14809.

1630. H.J. Muller-Eberhard, “The killer molecule of complement,” J. Invest. Dermatol. 85(July 1985):47s-52s.

1631. J.H. Humphrey, R.R. Dourmashkin, “The lesions in cell membranes caused by complement,” Adv. Immunol. 11(1969):75-115. See also: T.R. Hesketh, R.R. Dourmashkin, S.N. Payne, J.H. Humphrey, P.J. Lachmann, “Lesions due to complement in lipid membranes,” Nature 233(29 October 1971):620-623.

1632. B.P. Morgan, “Mechanisms of tissue damage by the membrane attack complex of complement,” Complement Inflamm. 6(1989):104-111.

1633. O. Krahenbuhl, J. Tschopp, “Involvement of granule proteins in T-cell-mediated cytolysis,” Nat. Immun. Cell Growth Regul. 9(1990):274-282.

1634. J.D. Young, C.C. Liu, P.M. Persechini, “Molecular mechanisms of lymphocyte-mediated killing,” Braz. J. Med. Biol. Res. 21(1988):1145-1153.

1635. A. Hameed, K.J. Olsen, M.K. Lee, M.G. Lichtenheld, E.R. Podack, “Cytolysis by Ca-permeable transmembrane channels. Pore formation causes extensive DNA degradation and cell lysis,” J. Exp. Med. 169(1 March 1989):765-777.

1636. S. Bhakdi, T. Tranum-Jensen, “Mechanism of complement cytolysis and the concept of channel-forming proteins,” Philos. Trans. R. Soc. Lond. B. Biol. Sci. 306(6 September 1984):311-324; “Membrane damage by channel-forming proteins: staphylococcal alpha-toxin, streptolysin-O and the C5b-9 complement complex,” Biochem. Soc. Symp. 50(1985):221-233.

1637. V. Sathyamoorthy, J.S. Huntley, A.C. Hall, R.H. Hall, “Biochemical and physiological characteristics of HlyA, a pore-forming cytolysin of Vibrio cholerae serogroup O1,” Toxicon. 35(April 1997):515-527; “Mmembrane attack induced by HlyA, a pore-forming toxin of Vibrio cholerae,” Hum. Exp. Toxicol. 16(February 1997):101-105.

1638. J. Tschopp, D. Masson, K.K. Stanley, “Structural/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis,” Nature 322(1986):831-834.

1639. J.D. Young, C.G. Peterson, P. Venge, Z.A. Cohn, “Mechanism of membrane damage mediated by human eosinophil cationic protein,” Nature 321(5-11 June 1986):613-616; P. Venge, J. Bystrom, “Eosinophil cationic protein (ECP),” Int. J. Biochem. Cell Biol. 30(April 1998):433-437.

1640. M.C. Peitsch, J. Tschopp, “Assembly of macromolecular pores by immune defense systems,” Curr. Opin. Cell Biol. 3(August 1991):710-716. See also: N.W. Andrews, C.K. Abrams, S.L. Slatin, G. Griffiths, “A T. cruzi-secreted protein immunologically related to the complement component C9: evidence for membrane pore-forming activity at low pH,” Cell 61(June 1990):1277-1287.

1641. J. Lundahl, C. Dahlgren, A. Eklund, J. Hed, R. Hernbrand, G. Tornling, “Quartz selectively down-regulates CR1 on activated human granulocytes,” J. Leukoc. Biol. 53(January 1993):99-103.

1642. M. Doherty, J.T. Whicher, P.A. Dieppe, “Activation of the alternative pathway of complement by monosodium urate monohydrate crystals and other inflammatory particles,” Ann. Rheum. Dis. 42(June 1983):285-291.

1643. A. Nicholson-Weller, C.E. Wang, “Structure and function of decay accelerating factor,” J. Lab. Clin. Med. 123(April 1994):485-491; A. Nicholson-Weller, “Decay accelerating factor (CD55),” Curr. Topics Microbiol. Immunol. 178(1992):7-30.

1644. A. Gorter, S. Meri, “Immune evasion of tumor cells using membrane-bound complement regulatory proteins,” Immunol. Today 20(December 1999):576-582.

1645. L. Tang, L. Liu, H.B. Elwing, “Complement activation and inflammation triggered by model biomaterial surfaces,” J. Biomed. Mater. Res. 41(August 1998):333-340.

1646. L. Liu, H. Elwing, “Complement activation on thiol-modified gold surfaces,” J. Biomed. Mater. Res. 30(April 1996):535-541.

1647. B. Paul Morgan, Claire L. Harris, Complement Regulatory Proteins, Academic Press, New York, 1999.

1648. R.J. Ziccardi, “The first component of human complement (C1): activation and control,” Springer Semin. Immunopathol. 6(1983):213-230.

1649. V. Nussenzweig, R. Melton, “Human C4-binding protein (C4-bp),” in L. Corand, ed., Methods in Enzymology, Part C, Proteolytic Enzymes, Vol. 80, Academic Press, London, 1981, pp. 124-133.

1650. P.F. Zipfel, T.S. Jokiranta, J. Hellwage, V. Koistinen, S. Meri, “The factor H protein family,” Immunopharmacology 42(May 1999):53-60.

1651. T. Oda, Y. Kojima, T. Akaike, S. Ijiri, A. Molla, H. Maeda, “Inactivation of chemotactic activity of C5a by the serratial 56-kilodalton protease,” Infect. Immun. 58(May 1990):1269-1272.

1652. S. Schonermark, E.W. Rauterberg, M.L. Shin, S. Loke, D. Roelcke, G.M. Hansch, “Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor,” J. Immunol. 136(1986):1772-1776; L.S. Zalman, L.M. Wood, H.J. Muller-Eberhard, “Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels,” Proc. Natl. Acad. Sci. (USA) 83(1986):6975-6979; L.S. Zalman, “Homologous restriction factor,” Curr. Top. Microbiol. Immunol. 178(1992):87-99.

1653. Y. Sugita, Y. Nakano, M. Tomita, “Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels,” J. Biochem. 104(1988):633-637; A. Davies, P.J. Lachmann, “Membrane defense against complement lysis: the structure and biological properties of CD59,” Immunol. Res. 12(1993):258-275.

1654. R.J. Johnson, M.D. Lelah, T.M. Sutliff, D.R. Boggs, “A modification of cellulose that facilitates the control of complement activation,” Blood Purif. 8(1990):318-328.

1655. B.R. Lucchesi, K.S. Kilgore, “Complement inhibitors in myocardial ischemia/reperfusion injury,” Immunopharmacology 38(December 1997):27-42.

1656. S.C. Makrides, “Therapeutic inhibition of the complement system,” Pharmacol. Rev. 50(March 1998):59-87;

1657. J.E. Marsh, J.R. Pratt, S.H. Sacks, “Targeting the complement system,” Curr. Opin. Nephrol. Hypertens. 8(September 1999):557-562.

1658. G.A Jarvis, V.A. Vedros, “Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation,” Infect. Immun. 55(January 1987):174-180.

1659. H. Smith, J.A. Cole, N.J. Parsons, “The sialylation of gonococcal lipopolysaccharide by host factors: a major impact on pathogenicity,” FEMS Microbiol. Lett. 79(15 December 1992):287-292.

1660. U. Vogel, S. Hammerschmidt, M. Frosch, “Sialic acids of both the capsule and the sialylated lipooligosaccharide of Neisseria meningitis serogroup B are prerequisites for virulence of meningococci in the infant rat,” Med. Microbiol. Immunol. (Berl.) 185(September 1996):81-87.

1661. C.M. Kahler, L.E. Martin, G.C. Shih, M.M. Rahman, R.W. Carlson, D.S. Stephens, “The (alpha2–>8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum,” Infect. Immun. 66(December 1998):5939-5947.

1662. P.A. Rice, D.P. McQuillen, S. Gulati, D.B. Jani, L.M. Wetzler, M.S. Blake, E.C. Gotschlich, “Serum resistance of Neisseria gonorrhoeae. Does it thwart the inflammatory response and facilitate the transmission of infection?” Ann. N.Y. Acad. Sci. 730(15 August 1994):7-14; D.P. McQuillen, S. Gulati, S. Ram, A.K. Turner, D.B. Jani, T.C. Heeren, P.A. Rice, “Complement processing and immunoglobulin binding to Neisseria gonorrhoeae determined in vitro simulates in vivo effects,” J. Infect. Dis. 179(January 1999):124-135.

1663. B. Wretlind, O.R. Pavlocskis, “Pseudomonas aeruginosa elastase and its role in Pseudomonas infections,” Rev. Infect. Dis. 5(November-December 1983):S998-S1004 (Suppl 5).

1664. J. Catanese, L.F. Kress, “Enzymatic inactivation of human plasma C1-inhibitor and alpha 1-antichymotrypsin by Pseudomonas aeruginosa proteinase and elastase,” Biochim. Biophys. Acta 789(28 August 1984):37-43.

1665. Y.Q. Hong, B. Ghebrehiwet, “Effect of Pseudomonas aeruginosa elastase and alkaline protease on serum complement and isolated components C1q and C3,” Clin. Immunol. Immunopathol. 62(February 1992):133-138.

1666. Y. Kon, H. Tsukada, T. Hasegawa, K. Igarashi, K. Wada, E. Suzuki, M. Arakawa, F. Gejyo, “The role of Pseudomonas aeruginosa elastase as a potent inflammatory factor in rat air pouch inflammation model,” FEMS Immunol. Med. Microbiol. 25(15 August 1999):313-321.

1667. H.A. Schenkein, “Failure of Bacteroides gingivalis W83 to accumulate bound C3 following opsonization with serum,” J. Periodontal Res. 24(January 1989):20-27; T. Nilsson, J. Carlsson, G. Sundqvist, “Inactivation of key factors of the plasma proteinase cascade systems by Bacteroides gingivalis,” Infect. Immun. 50(November 1985):467-471.

1668. B. China, M.P. Sory, B.T. N’Guyen, M. De Bruyere, G.R. Cornelis, “Role of the YadA protein in prevention of opsonization of Yersinia enterocolitica by C3b molecules,” Infect. Immun. 61(August 1993):3129-3136.

1669. R.D. Horstmann, H.J. Sievertsen, J. Knobloch, V.A. Fischetti, “Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H,” Proc. Natl. Acad. Sci. (USA) 85(March 1988):1657-1661.

1670. E.J. Heffernan, S. Reed, J. Hackett, J. Fierer, C. Roudier, D. Guiney, “Mechanism of resistance to complement-mediated killing of bacteria encoded by the Salmonella typhimurium virulence plasmid gene rck,” J. Clin. Invest. 90(September 1992):953-964.

1671. F.C. Eisenschenk, J.J. Houle, E.M. Hoffmann, “Mechanism of serum resistance among Brucella abortus isolates,” Vet. Microbiol. 68(31 August 1999):235-244.

1672. E. Rokita, A. Makristathis, E. Presterl, M.L. Rotter, A.M. Hirschl, “Helicobacter pylori urease significantly reduces opsonization by human complement,” J. Infect. Dis. 178(November 1998):1521-1525.

1673. K.L. McCallum, G. Schoenhals, Laakso, B. Clarke, C. Whitfield, “A high-molecular-weight fracftion of smooth lipopolysaccharide in Klebsiella serotype O1:K20 contains a unique O-antigen epitope and determines resistance to nonspecific serum killing,” Infect. Immun. 57(December 1989):3816-3822.

1674. H.L. Jessop, P.A. Lambert, “The role of surface polysaccharide in determining the resistance of Serratia marcescens to serum killing,” J. Gen. Microbiol. 132(September 1986):2505-2514.

1675. S.V. Narayana, M. Carson, O. el-Kabbani, J.M. Kilpatrick, D. Moore, X. Chen, C.E. Bugg, J.E. Volanakis, L.J. DeLucas, “Structure of human factor D. A complement system protein at 2.0 A resolution,” J. Mol. Biol. 235(14 January 1994):695-708.

1676. F.R. Taylor, S.A. Bixler, J.L. Budman, D. Wen, M. Karpusas, S.T. Ryan, G.J. Jaworski, A. Safari-Fard, S. Pollard, A. Whitty, “Induced fit activation mechanism of the exceptionally specific serine protease, complement factor D,” Biochemistry 38(2 March 1999):2849-2859.

1677. S.R. Barnum, M.A. Niemann, J.F. Kearney, J.E. Volanakis, “Quantitation of complement factor D in human serum by a solid-phase radioimmunoassay,” J. Immunol. Methods 67(16 March 1984):303-309.

1678. F. Praz, M.C. Barreira, P. Lesavre, “A one-step procedure for preparation of classical pathway (C1q) and alternative pathway (factor D) depleted human serum,” J. Immunol. Methods 50(1982):227-231.

1679. A.G. Sjoholm, B. Selander, S. Ostenson, E. Holmstrom, C. Soderstrom, “Normal human serum depleted of C1q, factor D and properdin: its use in studies of complement activation,” APMIS 99(December 1991):1120-1128.

1680. Richard D. Schaub, Marina V. Kameneva, Harvey S. Borovetz, William R. Wagner, “Assessing acute platelet adhesion on opaque metallic and polymeric biomaterials with fiber optic microscopy,” J. Biomed. Mater. Res. 49(2000):460-468.

1681. H.H. Leveen, J.R. Barbario, “Tissue reaction to plastics used in surgery with special reference to Teflon,” Ann. Surg. 74(1949):129.

1682. G.E. Arnold, “Vocal rehabilitation of paralytic dysphonia: Technique of intracordal injection,” Arch. Otolaryngol. 76(1962):358-368.

1683. T.B. Blandford, P.J. Seamon, R. Hughes, M. Pattison, M.P. Wilderspin, “A case of polytetrafluoroethylene poisoning in cockatiels accompanied by polymer fume fever in the owner,” Vet. Rec. 96(22 February 1975):175-178; Darrel K. Styles, “TeflonTM poisoning: The silent killer,” 1998,; Kelly Greaser, “How Teflon Kills your Bird!” or; Joanie Doss, “The Silent Killer,” The Alaska Bird Club Newsletter, 1995,; “Teflon Warning!”; “Teflon Poisoning,”

1684. D.M. Lublin, J.P. Atkinson, “Decay-accelerating factor: biochemistry, molecular biology, and function,” Ann. Rev. Immunol. 7(1989):35-58.

1685. M.K. Liszewski, T.W. Post, J.P. Atkinson, “Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster,” Ann. Rev. Immunol. 9(1991):431-455.

1686. B.F. Murphy, J.R. Saunders, M.K. O’Bryan, L. Kirszbaum, I.D. Walker, A.J. d’Apice, “SP-40,40 is an inhibitor of C5b-6-initiated haemolysis,” Int. Immunol. 1(1989):551-554; L. Kirszbaum, J.A. Sharpe, B. Murphy, A.J. d’Apice, B. Classon, P. Hudson, I.D. Walker, “Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: a link between the complement and reproductive systems,” EMBO J. 8(March 1989):711-718; M.K. O’Bryan, H.W. Baker, J.R. Saunders, L. Kirszbaum, I.D. Walker, P. Hudson, D.Y. Liu, M.D. Glew, A.J. d’Apice, B.F. Murphy, “Human seminal clusterin (SP-40,40). Isolation and characterization,” J. Clin. Invest. 85(May 1990):1477-1486.

1687. N.H. Choi, Y. Nakano, T. Tobe, T. Mazda, M. Tomita, “Incorporation of SP-40,40 into the soluble membrane attack complex (SMAC, SC5b-9) of complement,” Int. Immunol. 2(1990):413-417.

1688. J.K. Tsuruta, K. Wong, I.B. Fritz, M.D. Griswold, “Structural analysis of sulphated glycoprotein 2 from amino acid sequence. Relationship to clusterin and serum protein 40,40,” Biochem. J. 268(15 June 1990):571-578.

1689. J. Tschopp, L.E. French, “Clusterin: modulation of complement function,” Clin. Exp. Immunol. 97(August 1994):11-14 (Suppl. 2).

1690. S. Meri, B.P. Morgan, A. Davies, R.H. Daniels, M.G. Olavesen, H. Waldmann, P.J. Lachmann, “Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers,” Immunology 71(September 1990):1-9.

1691. D.E. Wexler, R.D. Nelson, P.P. Cleary, “Human neutrophil chemotactic response to group A streptococci: bacteria-mediated interference with complement-derived chemotactic factors,” Infect. Immunity 39(January 1983):239-246; D.E. Wexler, D.E. Chenoweth, P.P. Cleary, “Mechanism of action of the group A streptococcal C5a inactivator,” Proc. Natl. Acad. Sci. (USA) 82(December 1985):8144-8148; P.P. Cleary, U. Prahbu, J.B. Dale, D.E. Wexler, J. Handley, “Streptococcal C5a peptidase is a highly specific endopeptidase,” Infect. Immun. 60(December 1992):5219-5223.

1692. B.P. Morgan, J.R. Dankert, A.F. Esser, “Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis,” J. Immunol. 138(1 January 1987):246-253; J.M. Stein, J.P. Luzio, “Ectocytosis caused by sublytic autologous complement attack on human neutrophils. The sorting of endogenous plasma-membrane proteins and lipids into shed vesicles,” Biochem. J. 274(1 March 1991):381-386.

1693. P.J. Sims, T. Wiedmer, “Repolarization of the membrane potential of blood platelets after complement damage: evidence for a Ca++-dependent exocytotic elimination of C5b-9 pores,” Blood 68(August 1986):556-561; P.J. Sims, E.M. Faioni, T. Wiedmer, S.J. Shattil, “Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity,” J. Biol. Chem. 263(5 December 1988):18205-18212.

1694. D.F. Carney, C.L. Koski, M.L. Shin, “Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9,” J. Immunol. 134(March 1985):1804-1809; D.F. Carney, C.H. Hammer, M.L. Shin, “Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+,” J. Immunol. 137(1 July 1986):263-270.

1695. K. Iida, M.B. Whitlow, V. Nussenzweig, “Membrane vesiculation protects erythrocytes from destruction by complement,” J. Immunol. 147(15 October 1991):2638-2642.

1696. J.C. Albrecht, J. Nicholas, K.R. Cameron, C. Newman, B. Fleckenstein, R.W. Honess, “Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59,” Virology 190(September 1992):527-530.

1697. M. Saifuddin, C.J. Parker, M.E. Peeples, M.K. Gorny, S. Zolla-Pazner, M. Ghassemi, I.A. Rooney, J.P. Atkinson, G.T. Spear, “Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1,” J. Exp. Med. 182(1 August 1995):501-509; G.T. Spear, N.S. Lurain, C.J. Parker, M. Ghassemi, G.H. Payne, M. Saifuddin, “Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses: human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV),” J. Immunol. 155(1 November 1995):4376-4381; M. Saifuddin, T. Hedayati, J.P. Atkinson, M.H. Holguin, C.J. Parker, G.T. Spear, “Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction,” J. Gen. Virol. 78(August 1997):1907-1911.

1698. M.P. Dierich, H. Stoiber, A. Clivio, “A `complementary’ AIDS vaccine,” Nature Med. 2(February 1996):153-155.

1699. M. Nakamura, H. Okada, H. Sasaki, K. Yoshida, M. Kamada, N. Okada, M. Terada, T. Ohno, “Quantification of the CD55 and CD59, membrane inhibitors of complement on HIV-1 particles as a function of complement-mediated virolysis,” Microbiol. Immunol. 40(1996):561-567.


Last updated on 16 April 2004